ArticleSurgery today2025
Impact of prophylactic 5-hydroxytryptamine-3 receptor antagonist on postoperative nausea and vomiting in patients undergoing laparoscopic or robotic colorectal cancer surgery: a propensity score-matched analysis.
Article in Surgery today, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposePostoperative nausea and vomiting (PONV) is a common complication of surgery. This study evaluated the efficacy of prophylactic 5-hydroxytryptamine-3 receptor antagonist (5HT3RA) in preventing PONV in patients undergoing laparoscopic or robotic colorectal cancer (CRC) surgery.
methodsBetween April and June, 2022, 100 consecutive patients received 5HT3RA prophylaxis before anesthesia induction. We compared these patients retrospectively with 368 patients who underwent similar procedures without 5HT3RA in 2021. Propensity score matching (PSM) was applied to reduce bias, resulting in two matched groups (n = 100 in each group).
resultsThe incidences of PONV, nausea, and vomiting in the entire cohort were 26.7%, 25.2%, and 10.4%, respectively. After PSM, no significant differences were found between the groups in clinical characteristics, anesthesia time, operative time, blood loss, time to first flatus, or length of postoperative hospital stay. Moreover, no significant differences were found in the incidences of PONV, nausea, or vomiting. Multivariate analyses identified female sex as an independent risk factor for PONV (P = 0.02 before PSM; P < 0.01 after PSM).
conclusionsThe findings of the present study using PSM analysis suggest that the prophylactic administration of 5HT3RA did not reduce the incidence of PONV in patients undergoing laparoscopic or robotic CRC surgery.
Indexed as
Identifiers
40586843What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.